The design of the world’s first non-invasive blood glucose monitoring device has won a prestigious European-wide award.

A version of Afon Technology’s Glucowear triumphed in the ‘Personal/Wellness and Beauty: Other Designs’ category of the European Product Design Award announced on Thursday, 19 December 2024.

Glucowear has been designed for Afon and submitted by the Medical Design Group www.Medical-Design-Group.com.

The award recognises and honours the expertise of international product and industrial designers who strive to improve our daily lives with their practical and well-thought-out creations.

Afon Technology is a Welsh-based tech firm committed to developing the world’s first non-invasive blood glucose monitoring device, which is tipped to transform the lives of those with diabetes.

Glucowear™ is Afon Technology’s pain-free continuous blood glucose monitor that is set to make life easier for people with diabetes by removing the need for needles when monitoring blood sugar levels.

Sabih Chaudhry, Afon Technology’s CEO, said: “We are incredibly proud that Glucowear has won this prestigious award. Well done to Tom Craven from Medical Design Group for not just this award, but for bringing our vision to life with the design.

“This award reflects Afon Technology’s bold and innovative commitment to creating technology to improve the lives of people with diabetes.

“Specialising in developing ground-breaking medical technology aimed at improving patient care and health outcomes, Afon Technology is dedicated to advancing healthcare through cutting-edge solutions.”

Afon Technology has won a number of awards, recently picking up the Health and Safety Gold Award, highlighting the company’s outstanding dedication to health and safety excellence.

For more information, please visit https://afontechnology.com/

Afon Technology has come a long way since the concept of its life changing technology was discovered in by Dr Sabih Chaudhry (Founder & CEO).

who worked with the Royal Liverpool Hospital in 2013 to conduct the first trials on the technology.